References
1. Munoz N, Castellsague X, de Gonzalez AB, Gissmann L. Chapter 1: HPV
in the etiology of human cancer. Vaccine. 2006;24 Suppl 3:S3/1-10.
2. Schiffman M, Castle PE, Jeronimo J, Rodriguez AC, Wacholder S. Human
papillomavirus and cervical cancer. Lancet. 2007;370(9590):890-907.
3. Arbyn M, Castellsague X, de Sanjose S, Bruni L, Saraiya M, Bray F, et
al. Worldwide burden of cervical cancer in 2008. Ann Oncol.
2011;22(12):2675-86.
4. Castellsague X. Natural history and epidemiology of HPV infection and
cervical cancer. Gynecol Oncol. 2008;110(3 Suppl 2):S4-7.
5. Arbyn M, Xu L. Efficacy and safety of prophylactic HPV vaccines. A
Cochrane review of randomized trials. Expert Rev Vaccines.
2018;17(12):1085-91.
6. Baseman JG, Koutsky LA. The epidemiology of human papillomavirus
infections. J Clin Virol. 2005;32 Suppl 1:S16-24.
7. Marty R, Roze S, Bresse X, Largeron N, Smith-Palmer J. Estimating the
clinical benefits of vaccinating boys and girls against HPV-related
diseases in Europe. BMC Cancer. 2013;13:10.
8. Martin-Hirsch PP, Paraskevaidis E, Bryant A, Dickinson HO. Surgery
for cervical intraepithelial neoplasia. Cochrane Database Syst Rev.
2013(12):CD001318.
9. Kyrgiou M, Athanasiou A, Paraskevaidi M, Mitra A, Kalliala I,
Martin-Hirsch P, et al. Adverse obstetric outcomes after local treatment
for cervical preinvasive and early invasive disease according to cone
depth: systematic review and meta-analysis. BMJ. 2016;354:i3633.
10. Jin G, LanLan Z, Li C, Dan Z. Pregnancy outcome following loop
electrosurgical excision procedure (LEEP) a systematic review and
meta-analysis. Arch Gynecol Obstet. 2014;289(1):85-99.
11. Bjorge T, Skare GB, Bjorge L, Trope A, Lonnberg S. Adverse Pregnancy
Outcomes After Treatment for Cervical Intraepithelial Neoplasia. Obstet
Gynecol. 2016;128(6):1265-73.
12. van der Heijden E, Lopes AD, Bryant A, Bekkers R, Galaal K.
Follow-up strategies after treatment (large loop excision of the
transformation zone (LLETZ)) for cervical intraepithelial neoplasia
(CIN): Impact of human papillomavirus (HPV) test. Cochrane Database Syst
Rev. 2015;1:CD010757.
13. Strander B, Andersson-Ellstrom A, Milsom I, Sparen P. Long term risk
of invasive cancer after treatment for cervical intraepithelial
neoplasia grade 3: population based cohort study. BMJ.
2007;335(7629):1077.
14. Ebisch RMF, Rutten DWE, IntHout J, Melchers WJG, Massuger L, Bulten
J, et al. Long-Lasting Increased Risk of Human Papillomavirus-Related
Carcinomas and Premalignancies After Cervical Intraepithelial Neoplasia
Grade 3: A Population-Based Cohort Study. J Clin Oncol.
2017;35(22):2542-50.
15. Soergel P, Makowski L, Schippert C, Staboulidou I, Hille U,
Hillemanns P. The cost efficiency of HPV vaccines is significantly
underestimated due to omission of conisation-associated prematurity with
neonatal mortality and morbidity. Hum Vaccin Immunother.
2012;8(2):243-51.
16. Pham CT, Juhasz M, Sung CT, Mesinkovska NA. The human papillomavirus
vaccine as a treatment for human papillomavirus-related dysplastic and
neoplastic conditions: A literature review. J Am Acad Dermatol.
2020;82(1):202-12.
17. Rosenberg T, Philipsen BB, Mehlum CS, Dyrvig AK, Wehberg S, Chirila
M, et al. Therapeutic Use of the Human Papillomavirus Vaccine on
Recurrent Respiratory Papillomatosis: A Systematic Review and
Meta-Analysis. J Infect Dis. 2019;219(7):1016-25.
18. Dion GR, Teng S, Boyd LR, Northam A, Mason-Apps C, Vieira D, et al.
Adjuvant Human Papillomavirus Vaccination for Secondary Prevention: A
Systematic Review. JAMA Otolaryngol Head Neck Surg. 2017;143(6):614-22.
19. Kang WD, Choi HS, Kim SM. Is vaccination with quadrivalent HPV
vaccine after loop electrosurgical excision procedure effective in
preventing recurrence in patients with high-grade cervical
intraepithelial neoplasia (CIN2-3)? Gynecol Oncol. 2013;130(2):264-8.
20. Downs SH, Black N. The feasibility of creating a checklist for the
assessment of the methodological quality both of randomised and
non-randomised studies of health care interventions. J Epidemiol
Community Health. 1998;52(6):377-84.
21. Samoocha D, Bruinvels DJ, Elbers NA, Anema JR, van der Beek AJ.
Effectiveness of web-based interventions on patient empowerment: a
systematic review and meta-analysis. J Med Internet Res. 2010;12(2):e23.
22. Giannella L, Mfuta K, Fodero C, Prandi S. Outcome of Nonpersonalized
Human Papillomavirus Vaccinations During Postconization Follow-up: A
Report of Two Cases. J Reprod Med. 2015;60(9-10):455-7.
23. Hildesheim A, Gonzalez P, Kreimer AR, Wacholder S, Schussler J,
Rodriguez AC, et al. Impact of human papillomavirus (HPV) 16 and 18
vaccination on prevalent infections and rates of cervical lesions after
excisional treatment. Am J Obstet Gynecol. 2016;215(2):212 e1- e15.
24. Garland SM, Paavonen J, Jaisamrarn U, Naud P, Salmeron J, Chow SN,
et al. Prior human papillomavirus-16/18 AS04-adjuvanted vaccination
prevents recurrent high grade cervical intraepithelial neoplasia after
definitive surgical therapy: Post-hoc analysis from a randomized
controlled trial. Int J Cancer. 2016;139(12):2812-26.
25. Joura EA, Garland SM, Paavonen J, Ferris DG, Perez G, Ault KA, et
al. Effect of the human papillomavirus (HPV) quadrivalent vaccine in a
subgroup of women with cervical and vulvar disease: Retrospective pooled
analysis of trial data. BMJ (Online). 2012;344(7851).
26. Ghelardi A, Parazzini F, Martella F, Pieralli A, Bay P, Tonetti A,
et al. SPERANZA project: HPV vaccination after treatment for CIN2.
Gynecol Oncol. 2018;151(2):229-34.
27. Van Hentenryck M, Noel JC, Simon P. Obstetric and neonatal outcome
after surgical treatment of cervical dysplasia. Eur J Obstet Gynecol
Reprod Biol. 2012;162(1):16-20.
28. Haupt RM, Wheeler CM, Brown DR, Garland SM, Ferris DG, Paavonen JA,
et al. Impact of an HPV6/11/16/18 L1 virus-like particle vaccine on
progression to cervical intraepithelial neoplasia in seropositive women
with HPV16/18 infection. Int J Cancer. 2011;129(11):2632-42.
29. de Vos van Steenwijk PJ, Ramwadhdoebe TH, Lowik MJ, van der Minne
CE, Berends-van der Meer DM, Fathers LM, et al. A placebo-controlled
randomized HPV16 synthetic long-peptide vaccination study in women with
high-grade cervical squamous intraepithelial lesions. Cancer Immunol
Immunother. 2012;61(9):1485-92.
30. Roman LD, Wilczynski S, Muderspach LI, Burnett AF, O’Meara A,
Brinkman JA, et al. A phase II study of Hsp-7 (SGN-00101) in women with
high-grade cervical intraepithelial neoplasia. Gynecol Oncol.
2007;106(3):558-66.